Mutant IDH1 inhibitor ivosidenib (IVO; AG-120) in combination with azacitidine (AZA) for newly diagnosed acute myeloid leukemia (ND AML).

Courtney D. DiNardo,Anthony S. Stein,Eytan M. Stein,Amir T. Fathi,Olga Frankfurt,Andre C. Schuh,Giovanni Martinelli,Prapti A. Patel,Emmanuel Raffoux,Peter Tan,Amer M. Zeidan,Stéphane de Botton,Hagop M. Kantarjian,Richard Stone,Du Hung Lam,Jing Gong,Vickie Zhang,Thomas Winkler,Bin Wu,Paresh Vyas

Mutant IDH1 inhibitor ivosidenib (IVO; AG-120) in combination with azacitidine (AZA) for newly diagnosed acute myeloid leukemia (ND AML).

2019

7011Background: IVO, a mutant IDH1 (mIDH1) inhibitor, is approved for the treatment of relapsed/refractory mIDH1 AML. We report results from an ongoing phase 1b study of patients (pts) with mIDH1 N...

Keywords:

Refractory
Pathology
Myeloid leukemia
Cancer research
Mutant
IDH1
Azacitidine
Medicine
newly diagnosed

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations